Charles Schwab Investment Management Inc. Boosts Holdings in Illumina, Inc. (NASDAQ:ILMN)

Charles Schwab Investment Management Inc. lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.0% in the third quarter, Holdings Channel reports. The firm owned 657,554 shares of the life sciences company’s stock after buying an additional 12,731 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Illumina were worth $85,752,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of ILMN. Versant Capital Management Inc raised its stake in Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. purchased a new position in shares of Illumina in the second quarter worth about $34,000. Massmutual Trust Co. FSB ADV boosted its position in Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after acquiring an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new stake in Illumina during the 2nd quarter valued at about $61,000. Finally, Mizuho Securities Co. Ltd. acquired a new stake in Illumina in the 2nd quarter valued at about $63,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

NASDAQ:ILMN opened at $144.36 on Thursday. The company has a market cap of $22.90 billion, a price-to-earnings ratio of -14.49 and a beta of 1.13. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 52 week low of $93.51 and a 52 week high of $156.66. The company has a fifty day simple moving average of $141.42 and a two-hundred day simple moving average of $125.53.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. Illumina’s revenue was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.33 EPS. As a group, equities analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ILMN shares. JPMorgan Chase & Co. boosted their target price on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Daiwa America upgraded Illumina to a “strong-buy” rating in a report on Friday, August 16th. StockNews.com began coverage on Illumina in a research note on Thursday, August 29th. They issued a “buy” rating for the company. Stephens boosted their price target on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Finally, Robert W. Baird raised their price objective on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.